Rebamipide

DB11656ApprovedInvestigationalSmall molecule

Rebamipide is a gastroprotective agent used in combination with other similar therapies (e.g. proton pump inhibitors) to treat gastritis and protect the gastric mucosa. Rebamipide has been investigated for the treatment of Stomach Ulcer, Keratoconjunctivitis Sicca, and Gastric Adenoma and Early Gastric Cancer.

Chemical structure of Rebamipide
Formula / weight
C19H15ClN2O4 · 370.79 g/mol (avg)
Code names
OPC-12759

Resolves to

Compound
UNIILR583V32ZRCAS90098-04-7ChEMBLCHEMBL1697771ChEBI93814PubChem5042
Clinical / RWD
ATCA02BX14
Structure
InChIKeyALLWOAVDORUJLA-UHFFFAOYSA-NSMILESOC(=O)C(CC1=CC(=O)NC2=C1C=CC=C2)NC(=O)C1=CC=C(Cl)C=C1
Targets
P21462FPR1

What you can answer from here — as of February 11, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
49Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
1ContraindicationEach with its own population and attribute set
Sign in
29Marketed productsAcross 3 countries and 21 labellers
Sign in
1ATC codeIncluding every combination product, plus 14 drug categories
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Rebamipide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In